Asensus Surgical Shares Rise 8% on FDA Approval of New Instruments
July 28 2021 - 10:02AM
Dow Jones News
By Chris Wack
Asensus Surgical Inc. shares were up 8% to $2.33 in early trade
Wednesday after the company said it has received Food & Drug
Administration 510(k) clearance for 5 mm diameter articulating
instruments, adding to the Senhance Surgical System technology
platform.
The medical device company said the articulating instruments
offer better access to difficult-to-reach areas of the anatomy by
providing two additional degrees of freedom. These instruments have
previously received CE Mark for use in the European Union.
Asensus Surgical's technology platform, the Senhance Surgical
System, is a digital laparoscopic platform that uses augmented
intelligence to provide unmatched performance and patient outcomes
through machine learning.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
July 28, 2021 09:54 ET (13:54 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.